



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2023 #5

February 3, 2023

INSIDE:

CBER Announces 2023 Guidance Agenda.....	2
Administration Plans to End COVID-19 Public Health Emergency in May	3
RESEARCH IN BRIEF	3
BRIEFLY NOTED.....	5
PEOPLE.....	5
Register for 2023 Advocacy Day	7
ABC Webinar: How to Attract, Recruit, and Retain Veterans.....	7
MEMBER NEWS.....	8
GLOBAL NEWS	8
CALENDAR.....	9
POSITIONS.....	9

FDA Holds Stakeholder Call on Proposed Shift to Individual Risk Assessment for Blood Donations

This week, Peter Marks, MD, PhD, director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER), and Admiral Rachel Levine, MD, assistant secretary for Health at the U.S. Department of Health and Human Services (HHS), hosted a stakeholder call to discuss and answer questions regarding the recently proposed draft guidance "Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products." A summary of the call is available to America's Blood Centers (ABC) members in [MCN 23-012](#). Highlights of the call included:

- the Administration plans to focus on safety and inclusivity and hope the proposed change will assist in the recruitment of high school and college-aged donors as well as increase the diversity of the blood supply;
- in response to a question from ABC on how the Administration will support messaging from the blood community that the final guidance will take time to implement, Dr. Marks indicated that in the coming weeks, FDA will organize a meeting with blood collectors to discuss expectation-setting in terms of timing;
- Dr. Marks reiterated that FDA is committed to moving to a final guidance as quickly as possible, with the goal of having it finalized before the end of the public health emergency, which President Biden has announced will end on May 11. Admiral Levine also added that there is a sense of urgency in making the changes, and it is likely there will not be significant changes from the draft to the final guidance;
- FDA anticipates that the proposed guidance would potentially result in more than 100,000 previous donors immediately requalifying; and
- based on Canadian deferral modeling and the FDA's own on modeling from U.S. population figures, the agency estimates an expected deferral rate of 0.5-0.75 percent.

A recording of the call, when available, will be uploaded to the FDA's YouTube channel "[Stakeholder Calls Playlist](#)." ABC has updated [talking points](#) and a [statement](#) on the draft guidance available to member blood centers.

(continued on page 2)



FDA Stakeholder Call (continued from page 1)

Additionally, ABC plans to submit comments on the draft guidance and encourages member blood centers to send suggested language for inclusion to [Justine Coffey, JD, LLM](#), director, Regulatory Affairs and Public Policy. ABC also encourages member blood centers to send their own letters on the draft guidance to FDA.

(Source: [MCN 23-012](#), 2/1/23) ◆

CBER Announces 2023 Guidance Agenda

The U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has [published](#) its guidance agenda for 2023. The agenda outlines the guidance and draft guidance documents that CBER "is considering for development" throughout the calendar year. Topics of note that the agency will look to address include:

- "Collection of Platelets by Automated Methods; Draft Guidance for Industry;
- Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical; Draft Guidance for Industry;
- Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements; Guidance for Industry;
- Blood Pressure and Pulse Donor Eligibility Requirements; Compliance Policy; Guidance for Industry; [and]
- Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen; Draft Guidance for Industry."

Topics categorized as tissue and advanced therapies that may be of interest included:

- "Considerations for the Use of Human- and Animal- Derived Materials and Components in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products; Draft Guidance for Industry;
- Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry; [and]
- Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products; Draft Guidance for Industry."

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

memberservices@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



CBER Guidance Agenda (continued from page 2)

America's Blood Centers will continue to provide updates to member blood centers on its advocacy efforts regarding the CBER guidance agenda as they become available. Please contact ABC Director of Regulatory Affairs and Public Policy [Justine Coffey, JD, LLM](#) with questions. A complete listing of the potential guidances is available on the FDA's [website](#).

(Source: FDA [Announcement](#), 1/30/23) 💧

Administration Plans to End COVID-19 Public Health Emergency in May

The Executive Office of the President issued a [statement](#) on January 30th that indicated the Administration will extend the COVID-19 public health emergency (PHE) until May 11th. The statement came in the wake of two bills introduced in the House that aimed to end both the COVID-19 national emergency and the PHE. It explains, “[a]t present, the Administration’s plan is to extend the emergency declarations to May 11, and then end both emergencies on that date. This wind-down would align with the Administration’s previous commitments to give at least 60 days’ notice prior to termination of the PHE. To be clear, continuation of these emergency declarations until May 11 does not impose any restriction at all on individual conduct with regard to COVID-19. They do not impose mask mandates or vaccine mandates. They do not restrict school or business operations. They do not require the use of any medicines or tests in response to cases of COVID-19.

The PHE is a separate declaration from the emergency use authorization (EUA) process, thus such authorizations will remain until they are revoked separately. On January 11th, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra, JD extended the COVID-PHE for another 90-days. The PHE allows several pandemic response measures and flexibility to continue. This includes changes to donor deferrals and [alternative procedures](#) for blood and blood components made by the FDA early in the pandemic, which are currently in effect until 60 days after the end of the PHE.

(Source: Administration [Statement](#) 1/30/23) 💧

RESEARCH IN BRIEF

Overuse of Immunoglobulin Therapy At Three Canadian Hospitals. An article in *Vox Sanguinis* presented [results](#) of “an audit” of immunoglobulin replacement therapy (IRT) in secondary immunodeficiencies (SID) at three British Columbia (BC) hospitals using “the Australian National Blood Authority/BloodSTAR Guidelines as a benchmark for appropriateness.” The authors explained that their research “included all patients who had IRT order with SID as indication between January 2018 and December 2019.” They noted that the primary outcome of the study required patients “[h]aving an eligible primary diagnosis, meeting SID criteria, an appropriate dosage, and follow-up immunoglobulin G (IgG) levels.” The study included 33 patients (28 percent) who “were newly started on IRT and 81 were chronically treated...There was a non-statistically significant higher rate of appropriate utilization in the new cohort (66.7 vs. 45.7 percent, $p = 0.06$). The most common reason for inappropriateness [was the] lack of IgG follow-up at 6 or 12 months (chronic 37 percent, new 21.2 percent, $p = 0.13$).” The researchers found that “[w]hen stratified by site, the most common reason for inappropriateness at each hospital was lack of 6- or 12-month follow-up, not meeting SID criteria, ineligible primary diagnosis, and inappropriate dose...Hospital Three had the most reasons for inappropriate use compared to Hospital One or Two (40 vs. 20 vs. 13)...Of those who did not meet the primary objective, having an ineligible primary diagnosis was the third and second most common reason for IRT inappropriateness in the chronic (10.3 percent) and new (33.3 percent) cohorts, respectively...Two patients in the chronic cohort did not have documented rationale

(continued on page 4)

RESEARCH IN BRIEF (continued from page 3)

for their out-of-range doses (0.18 and 1 g/kg/cycle).” The authors explained that “[t]he dispensing hospital (Hospital One RR: 4.15, confidence interval [CI]: 1.67–8.36; Hospital Two RR: 6.60, CI: 2.62–11.52), use of subcutaneous immunoglobulin (RR: 3.84, CI: 0.93–10.54), IgG ordering at initiation (RR: 3.51, CI: 1.23–8.07), and having electronic medical record (EMR) documentation of clinical benefit (RR: 4.70; CI: 1.81–9.55) were all factors that remained statistically significantly associated with the primary outcome after multivariable analysis.” The researchers added that “[l]onger IRT duration had a lower association with appropriateness.” They concluded, “in both SID patients who have been maintained on IRT for years and newly started patients, there are high rates of inappropriate IRT usage in our jurisdiction when compared to stringent guidelines.”

Contributed by Richard Gammon, MD, Medical Director at OneBlood

Citation: Tran, A., Marcon, K., Zamar, D., *et al.*, “[Evaluation of immunoglobulin replacement therapy in secondary immunodeficiency at three British Columbia hospitals.](#)” *Vox Sang.* 2023.

Transfusion Medicine Reviews Highlights 12 “Noteworthy Papers from 2022. The editorial review board of *Transfusion Medicine Reviews* has [published](#) a synopsis of 12 papers from the past year that are recommended and may be of interest to the transfusion medicine community. The recommendations not only include a summary of each paper, but also feature an explanation of the significance of the research. Each paper has been segmented into three categories: randomized trials, retrospective studies and research reports, and clinical guidelines. The papers included:

- Randomized Trials:
 - Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomized, controlled, phase 3 trial ([Lancet](#));
 - Prehospital lyophilized plasma transfusion for trauma-induced coagulopathy in patients at risk for hemorrhagic shock ([JAMA](#));
 - Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial ([Blood](#));
 - Tranexamic acid in patients undergoing noncardiac surgery ([New England Journal of Medicine](#));
 - Tranexamic acid for safer surgery: the time is now ([British Journal of Surgery](#));
 - Prothrombin complex concentrate vs. plasma for post-cardiopulmonary bypass coagulopathy and Bleeding: A Randomized Clinical Trial ([JAMA Surgery](#));
 - Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial ([Blood](#));
- Retrospective Studies and Research Reports:
 - Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study ([Lancet Respiratory Medicine](#));
 - Comparing unbalanced and balanced ratios of blood products in massive transfusion to pediatric trauma patients: effects on mortality and outcomes ([European Journal of Trauma and Emergency Surgery](#));
 - Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness ([Journal of Clinical Investigation Insight](#));
 - Effect of unmanned aerial vehicle (drone) delivery on blood product delivery time and wastage in Rwanda: a retrospective, cross-sectional study and time series analysis ([Lancet Global Health](#));

(continued on page 5)



RESEARCH IN BRIEF (continued from page 4)

- First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative ([Blood Advances](#));
- Clinical Guidelines:
 - EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis ([Journal of Hepatology](#)).

Citation: Dzik, S. and Murphy, M. “[Recommended papers of 2022 from the TMR Editorial Board](#).” *Transfusion Medicine Reviews*. 2022. 💧

BRIEFLY NOTED

According to data [reported](#) in the “National Hospital Flash Report: January 2023” from Kaufman Hall, hospitals and health systems experienced their “worst financial year since the start of the COVID-19 pandemic.” The report also explained that “median Kaufman Hall Year-To-Date (YTD) Operating Margin Index reflecting actual margins was 0.2 percent in December, the only month in 2022 where hospitals realized positive YTD margins. Despite the end-of-year upswing, approximately half of U.S. hospitals finished 2022 with a negative margin as growth in expenses outpaced revenue increases.” Other takeaways included:

- “financial pressures driven by labor expenses;
- outpatient settings see increased volume; [and]
- success in 2023 tied to learning lessons of 2022.

The full report is available [here](#).

(Source: Kaufman Hall, [National Hospital Flash Report: January 2023](#), 1/30/23) 💧

PEOPLE

Alan Watson has been [named](#) president and chief executive officer (CEO) at MEDIC Regional Blood Center effective March 13th. According to a blood center announcement, Mr. Watson has 30 years of experience in healthcare administration, and he most recently served as the interim CEO of LifePoint Health System. “[Mr. Watson] brings a “strong background in organizational leadership,” said Jack Bryan board chair at MEDIC in the blood center announcement. “[His] experience serving as CEO of several hospitals and health systems will bring a global view of administration and community to his new role in the blood banking industry.” Additionally, Mr. Watson has “served as the CEO for hospitals in Cleveland, Knoxville, and Columbia, Tenn. [He] has a B.S. in Nuclear Medicine Technology, an M.S. in Community Health Administration, and an M.A. in Health Law and Policy.” He succeeds Jim Decker, DHA, FACHE who previously announced his [retirement](#) in July 2022.



(Source: MEDIC Regional Blood Center [Announcement](#), 1/31/23)

(continued on page 6)





PEOPLE (continued from page 5)



Tisha Foster, MD, FCAP has become OneBlood's vice president of Scientific, Medical, and Technical (SMT) Services and Research. According to a blood center announcement, in this role Dr. Foster will "oversee the SMT and Research Division of OneBlood and assume responsibility for all operational, financial, and business development aspects." She began her "career as a medical director at BloodNetUSA in Lakeland, Fla. in 2006. She later joined Florida's Blood Centers in Orlando, Fla. as chief medical affairs officer and when OneBlood was formed in 2012 she was named medical director. Throughout her career, Dr. Foster has provided expertise in the areas of therapeutic apheresis and cellular therapies, including oversight of the budget and operations of OneBlood's Medical Services team of more than 30 apheresis nurses. She also oversees OneBlood's Cellular Processing and Manufacturing area, which provides processing, cryopreservation, and storage of bone marrow and apheresis products. Dr. Foster received her medical degree and completed her training in Pathology at the University of Oklahoma College of Medicine and completed a Blood Banking/Transfusion Medicine fellowship at the Medical College of Wisconsin/BloodCenter of Wisconsin. She is board certified in Clinical Pathology as well as Blood Banking/Transfusion Medicine."

(Source: OneBlood Announcement, 1/31/23)



Houchin Community Blood Bank has [named Jonathan Bautista](#) CEO and chief operating officer (COO). According to *The Bakersfield Californian*, Mr. Bautista is "an executive with some 20 years of experience in blood banking" and brings expertise in "strategic growth decisions, transforming operational processes, and identifying short- and long-term benefits. Mr. Bautista stated in a news release, "I'm excited to join the Houchin Community Blood Bank family and to be a part of the Bakersfield community. Houchin Community Blood Bank in partnership with the community of blood donors has been saving lives since

1951, and my hope is that we continue to grow our donor community to ensure there is an ample supply of life-saving blood and blood products."

(Source: *The Bakersfield Californian*, [Houchin Community Blood Bank appoints fifth CEO in four years](#), 1/25/23) 💧



ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

Register for 2023 Advocacy Day

[Register](#) today for America's Blood Centers' (ABC) [2023 Advocacy Day](#) on April 26th. This event now takes place as part of Blood Advocacy Week April 24th-28th. Advocacy Day provides an opportunity for member blood centers to connect with members of Congress and their staffs to discuss the ongoing work at your blood center and the work done collectively by ABC and community blood centers to advance the ABC Advocacy Agenda. We encourage individuals to let your voice be heard as ABC will arrange meetings for you with your members of Congress and provide additional resources to help inform them and their staff about the latest policies impacting the blood community. This is your chance to take advantage of this virtual setting to easily meet with your local Congressional leaders and build relationships. Each person from your blood center who would like to participate in Advocacy Day must register individually. ABC will arrange for group visits but will need information for each person in attendance. Additional details, including the 2023 Advocacy Agenda, will be forthcoming. Please direct any questions to ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#).

(Source: ABC [Announcement](#), 1/18/23) 💧

ABC Webinar: How to Attract, Recruit, and Retain Veterans

[Registration](#) is open to ABC member blood centers for the webinar titled "How to Attract, Recruit, and Retain Veterans." Member blood centers are invited to join this event to hear Billy Wright, the national employment coordinator at the Department of Veterans Affairs, and Yolanda Rayford, the chapter director of the Baltimore/Chesapeake Region of Blue Star Families, discuss the latest resources and strategies available to help blood centers attract, recruit, and retain veterans and their spouses as part of your workforce. This webinar will take place on February 9th from 2-3 p.m. EST.

Upcoming ABC Webinars – Don't Miss Out!

- **ABC Webinar: How to Attract, Recruit, and Retain Veterans** – February 9 from 2-3 PM EST. [Registration](#) is open to ABC members. More information available in [MCN 23-014](#).
- **ABC Human Resources Forum Call** – February 27 from 2-3 PM EST. More information available in [MCN 23-014](#) including a link to join the call.
- **ABC Scientific, Medical, and Technical Committee Journal Club Webinar** – March 29 from 3-4 PM EDT. More information coming soon.



America's Blood Centers®
It's About *Life*.





MEMBER NEWS



South Texas Blood & Tissue recently [celebrated](#) the fifth anniversary of its “lifesaving whole-blood donor program,” formerly known as “Brothers in Arms” but has been rebranded to “Heroes in Arms,” in an event that reunited 10-year-old Mayah Zamora, a Uvalde school shooting survivor, with the blood donors who helped save her life. Accompanied by her parents, Maya and her family thanked everyone that played a role in her care following the mass shooting. “We’re forever grateful to the people who saved my life,” said Mayah according to a blood center news release. “I hope my story will let people know how important donating

blood is to saving lives.” The Heroes in Arms program “provides whole blood to emergency responders and follows research by the U.S. Army showing improved survival rates for trauma patients who were transfused whole blood, as opposed to blood that has been separated into its three major components (plasma, platelets and red [blood] cells.)” The program began five years ago and originally sought “male donors with type O-positive blood and low levels of certain antibodies [but, a] combination of greater demand and new screening has allowed South Texas Blood & Tissue to open the program to certain female donors,” which led to the program’s rebrand.

(Source: South Texas Blood & Tissue [News Release](#), 1/28/23) 💧

GLOBAL NEWS

The Kirby Institute has [published](#) the findings from the “[Transfusion-transmissible Infections \(TTI\) in Australia: Surveillance Report 2022](#).” Key findings in the report include:

- “over the ten-year period 2012–2021, there were over 13.8 million blood donations in Australia with an average of 1.4 million donations per year;
- in 2021, a total of 195 blood donors were detected as positive for a TTI for which testing is in place, namely, hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human T cell lymphotropic virus (HTLV), or active syphilis;
- consistent with the long-term pattern, the most common TTI was HBV, followed by HCV. Of all the donations positive for a TTI in 2021, 83.2% were positive for either HBV or HCV;
- overall HIV was the least common TTI among all donors in 2021, with just two donors testing positive; and
- [n]o transfusion transmitted HBV, HCV, HIV, HTLV or syphilis infections were reported in Australia in 2021.

The report is a collaboration “produced by the Australian Red Cross Lifeblood and the Kirby Institute via the Surveillance Evaluation and Research Program, which is responsible for monitoring the pattern of transmission of HIV, viral hepatitis, and specific sexually transmissible infections in Australia. This report summary[z]es donation testing data, and incidence and prevalence trends for transfusion transmissible infections (TTIs) among Australian blood donors.”

(Source: Kirby Institute [Report](#), 12/22) 💧



CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2023

Feb. 7. **U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) Town Hall: Clinical Development of Gene Therapy Products for Rare Diseases.** [Registration](#) is open. Additional information is available [here](#).

Feb. 9. **ABC Webinar: How to Attract, Recruit, and Retain Veterans.** [Registration](#) is open to ABC members. Additional information available [here](#).

Feb. 27. **ABC Human Resources Forum Call.** Additional information including a link to join the call available [here](#).

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** [Registration](#) is open. Additional information is available [here](#).

Mar. 29. **ABC Scientific, Medical, and Technical Committee Journal Club Webinar.** More information coming soon.

April 24-28. **ABC Blood Advocacy Week.** More information available [here](#).

April 26. **ABC Advocacy Day.** [Registration](#) is open. More information available [here](#).

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** [Registration](#) is open. Additional information is available [here](#).

May 10-11. **29th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Bologna, Italy.** More information available [here](#).

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#). 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Content Design Strategist (Oklahoma City, Oklahoma). Our Blood Institute is seeking a Content Design Strategist to join our community relations team. This role will function primarily as a graphic designer who will illustrate concepts based on discussions with internal stakeholders. The ideal candidate has the imagination, ability, and good humor to help bridge the gap between broad idea strategy and final execution of design, which includes a proficiency with copywriting. Duties include intensive collaboration with team members to establish design needs, using design software to complete projects, and revising projects based on internal feedback in a

timely, positive manner. This role requires excellent time management skills and flexibility and an unflappable demeanor to handle ever-changing priority projects. The Content Design Strategist will design and manage effective graphic content and communications including but not limited to print and digital advertising, print publicity pieces, promotional T-shirt designs, branded templates, social media posts, web content, brochures, and more. Qualifications: Associates degree required, experience in

(continued on page 10)

POSITIONS (continued from page 9)

graphic design required, experience with Adobe Creative Suite programs for creative development, etc. Salary Range: Competitive salary with excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, tuition reimbursement, and holiday pay. **How to apply:** <http://obi.org/careers/>

Chief Executive Officer (Flowood, MS). Mississippi Blood Services makes a difference in people's lives every day. With the support of the community and voluntary blood donors, we have been serving the needs of hospital patients since 1979. To help us meet our mission, as part of a planned retirement, we are looking for a new Chief Executive Officer with the necessary expertise to direct all functions of the corporation in accordance with Board directives and regulatory guidelines in order to attain strategic objectives. The CEO will provide leadership to provide exceptional service and products to hospitals giving maximum consideration to the safety and efficiency of those products and services, direct overall operation of the corporation, ensure implementation of established policies and acts as liaison with the Board of Directors, and maintain positive relationships with the business and medical community, civic groups, and other blood banking organizations. Education and/or Experience: Bachelor's degree (B.A.) or higher from a four-year college or university; 10 years of related experience preferably with either large nonprofits or blood services/products organizations; or equivalent combination of education and experience. Click [here](#) to view the full job description. Mississippi Blood Services is an equal opportunity employer and makes employment decisions without regard to race, color, sex, religion, national origin, age, disability, veteran status, genetic information, sexual orientation or gender identity. Please submit cover letter, resume and salary requirements to Kiffany Lee, Director of Human Resources klee@msblood.com.

Director, Scientific and Technical Operations. America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a **Director, Scientific and Technical Operations**. The position will lead the association's evaluation and response to new Scientific, Medical, Technical Operations, Quality and Regulatory (SMTQR) developments, including the development of programs and resources. The position will report directly to the Senior Director, Federal Government Affairs, providing strategic guidance on emerging trends in the blood community and transfusion medicine to help shape strategies that leverage the ABC membership to drive ABC's advocacy work. Primary Responsibilities: Direct the development of programs and resources that support member activities in SMTQR and operational areas, including Journal Club, Blood Bulletin, workshops, and webinars. Convene ABC members to share best practices and collaborate in advancing ABC's advocacy agenda and hot topics of importance to blood centers. Assist in the analysis of new standards, guidelines, and regulations. Provide consultative services to ABC member requests for information and assistance in SMTQR areas. Serve as the primary staff liaison to the ABC Quality Committee and subcommittees, and Quality and HR Forums. Oversee ABC's research, benchmarking, and survey programs, including the use of the data to improve member blood center operations and the identification of best practices. Educational Requirements: Bachelor's required. Experience, Knowledge, Skills, and Abilities: A minimum of five years of experience in blood banking, with emphasis in any of the areas of scientific, medical, quality, technical operations, and/or regulatory affairs. Blood center operational experience a plus. Possesses demonstrated analytic and communication skills. Strong customer service orientation and ability to navigate and respond to sensitive/ difficult situations. Self-motivated, flexible, creative, innovative, and goal oriented. This position is virtual. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to careers@americasblood.org.



Assistant Director, Donor Services. Hoxworth Blood Center is recruiting for an Assistant Director, Donor Services, to provide guidance to the Donor Services operation. The candidate will ensure compliance with federal, state, and local regulations, as well as Hoxworth Blood Center Standard Operating Procedures. The Assistant Director enforces current strategic planning initiatives; develops new activities and department goals in support of the blood center strategic plan. Directs automated collections, therapeutic/research apheresis activities, and proper storage and handling of all blood products. Develops processes to continually monitor operations to ensure high quality customer service; evaluates attainment of recruitment and collection goals. Prepares departmental budget and reviews expenditures

(continued on page 11)

POSITIONS (continued from page 10)

to ensure containment. Initiates acquisition and maintenance of all materials/supplies for the efficient operation of the department. Recommends and provides training to promote leadership and management skills. Develops and implements interdepartmental activities to encourage partnership with Donor Recruitment staff. Provides direct supervision to exempt and non-exempt staff. Performs related duties based on departmental need. Requirements: Bachelor's degree, nine (9) years of relevant work experience and/or other specialized training; five (5) years of experience in healthcare; three (3) years supervision. Apply here to Requisition # 49502 - <https://bit.ly/3igELMw>

Registered Nurse (Gainesville, FL and Jacksonville, FL). LifeSouth Community Blood Centers is seeking Registered Nurses in Gainesville, FL and Jacksonville, FL. This position is responsible for traveling to area hospitals to perform apheresis procedures alongside hospital staff. The RN will perform routine and complex therapeutic plasma exchanges, red cell exchanges, stem cell collections, white cell depletions and platelet reductions. Minimum qualifications include ASN/BSN, at least two years' experience as a nurse, meet hospital credentialing requirements and be licensed in the State of Florida. Apheresis training provided. Visit our [careers page](#) to learn more about LifeSouth and to apply.

Cellular Therapy Scientist (Gainesville, FL). LifeSouth Community Blood Centers is seeking a Cellular Therapy Scientist in Gainesville, FL. This position is responsible for performing and developing testing, processes, troubleshooting and investigation related to cellular therapy and manufactured biologics. Duties and projects may relate to products intended for research, commercial and clinical use. Minimum qualifications include a bachelor's degree in Clinical Lab, Chemical or Biological Science, knowledge of cGMP regulations and FDA guidelines applicable to biologics and cell therapy manufacturing. The ideal candidate will possess national certifications such as MLS (ASCP or AMT) or CABP from AABB. Visit our [careers page](#) to learn more about LifeSouth and to apply.

President and CEO. LifeStream Blood Bank, headquartered in San Bernardino, California, an independent blood center serving 80 hospitals in 6 counties in Southern California is seeking a President and CEO to lead the organization. Reporting to the Chair, Board of Directors, the preferred candidate is one who has demonstrated successful leadership in other blood centers or healthcare related organizations. The successful candidate must possess strong strategic planning skills to navigate a competitive environment and strong interpersonal and communication skills to develop strong relationships in the community and within the organization. Primary emphasis for this position is to ensure effective beneficial

business/service affiliations, strong community supported blood donor collections, loyal employee relations, solid asset management and ongoing financial stability. The candidate must have at least five years-experience serving as an executive team member (reporting to CEO) and/or CEO for a blood center or healthcare organization and hold a bachelor's degree from an accredited college or university. A graduate degree such as MBA, MHA, MPH, or equivalent is preferred. Competitive salary, relocation package and excellent benefits. Candidate must relocate full time to San Bernardino/Riverside area. Please submit cover letter, resume and salary requirements to Judy Taylor, Director, Human Resources at taylorju@lstream.org. The deadline for applications is **February 3, 2023**.

Chief Medical Officer. America's Blood Centers (ABC), North America's largest network of community based, independent blood programs, is seeking a **Chief Medical Officer**. Reporting to the Chief Executive Officer (CEO), the Chief Medical Officer (CMO) is responsible for implementing strategies and tactics, consistent with the best scientific and medical evidence and regulatory requirements, that support America's Blood Centers' (ABC) mission, maintain our values, and realize our vision. The CMO works as part of the ABC Senior Executive Team (SET) to communicate ABC's issues to members, regulators, legislators, the media, and external groups and mobilizes ABC members and professional staff to achieve the strategic goals of the organization. Primary Responsibilities: Represent independent non-profit community blood centers on scientific, medical, and technical matters as well as donor and patient safety concerns before federal agencies, industry, and other business partners, allied domestic and international organizations, scientific societies, the media, and the public. Education & Experience: Medical Degree required. U.S. medical license required with board certification in a medical specialty. Board certification in pathology, transfusion medicine, hematology, or infectious disease preferred. Ten or more years' experience related to blood banking or transfusion medicine. Three or more years' experience with healthcare and/or blood banking issues at a national level via committee work, offices held, or other appropriate experience. Administrative experience in a leadership role preferred. Work Environment and Conditions: This position is a consultant with an expected 40-60 hours per month. Additional time may be required (and paid) for travel. The CMO office may be located anywhere in the United States with travel to the ABC Washington, D.C. office as required and domestic travel on behalf of ABC to ABC meetings, to interact with government decision makers, and to liaison with external organizations as assigned. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to careers@americasblood.org.

(continued on page 12)



POSITIONS (continued from page 11)

Manager of Donor Resources. The Blood Connection is seeking a Manager of Donor Resources in Charlotte, N.C. and Greenville, S.C. to provide oversight to our recruitment teams within these divisions. This position directs Account Managers and Business Development Representatives to strategically manage our existing portfolio of blood donor groups and new business to reach collection targets. The Manager of Donor Resources monitors progress to goal proactively and effectively coaches and manages the team to success. The ideal candidate will have a strong background in territory management and team building. Candidates must possess excellent interpersonal, analytical, and strategic planning abilities. We offer an exceptional benefits package including a generous 401k match, 30 days PTO, company bonuses, tuition reimbursement, cell phone stipend, and yearly increases. Join one of the fastest growing blood centers in the country and help make an impact in your community today! How to apply: [Manager of Donor Resources Application](#)

